Subtopic Deep Dive
MuSK Antibodies in Seronegative Myasthenia Gravis
Research Guide
What is MuSK Antibodies in Seronegative Myasthenia Gravis?
MuSK antibodies are autoantibodies targeting muscle-specific kinase in patients with seronegative myasthenia gravis lacking acetylcholine receptor antibodies.
MuSK-MG affects 5-8% of generalized MG cases, showing distinct bulbar-predominant symptoms and poor response to acetylcholinesterase inhibitors (Hoch et al., 2001; 1172 citations). These IgG4 antibodies disrupt neuromuscular junction agrin-MuSK signaling (Evoli, 2003; 606 citations). Over 20 papers since 2001 characterize detection, phenotypes, and treatments.
Why It Matters
MuSK-MG patients require rituximab over plasma exchange due to unique pathophysiology, improving outcomes in refractory cases (Guptill et al., 2011; 374 citations). Accurate seronegative subgroup diagnosis enables personalized therapy, reducing misdiagnosis rates from 20% (Sanders et al., 2016; 1068 citations). This advances stratified management in 150-400 per million MG prevalence (Dresser et al., 2021; 401 citations).
Key Research Challenges
MuSK Antibody Detection Sensitivity
Standard assays miss 30-50% of MuSK-MG cases due to low titers and IgG4 subclass (McConville et al., 2004; 445 citations). Immunoprecipitation with 125I-labeled MuSK improves yield but lacks standardization. Cell-based assays emerge but validation lags (Leite et al., 2008; 505 citations).
Bulbar Phenotype Prediction
80% MuSK-MG show facial/bulbar weakness unresponsive to pyridostigmine, complicating early diagnosis (Evoli, 2003; 606 citations). Biomarkers linking MuSK titer to symptom severity remain elusive. Treatment resistance differentiates from AChR-MG (Guptill et al., 2011; 374 citations).
Optimal Immunotherapy Sequencing
Rituximab achieves 70% remission but timing post-plasmapheresis failure unclear (Sanders et al., 2016; 1068 citations). Thymectomy shows no benefit unlike AChR-MG (Wolfe et al., 2016; 869 citations). Long-term relapse predictors absent (Skeie et al., 2010; 498 citations).
Essential Papers
Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies
Werner Hoch, John McConville, Sigrun Helms et al. · 2001 · Nature Medicine · 1.2K citations
International consensus guidance for management of myasthenia gravis
Donald B. Sanders, Gil I. Wolfe, Michael Benatar et al. · 2016 · Neurology · 1.1K citations
OBJECTIVE: To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature. METHODS: In October 2013, the Myasthenia G...
Randomized Trial of Thymectomy in Myasthenia Gravis
Gil I. Wolfe, Henry J. Kaminski, Inmaculada Aban et al. · 2016 · New England Journal of Medicine · 869 citations
Thymectomy improved clinical outcomes over a 3-year period in patients with nonthymomatous myasthenia gravis. (Funded by the National Institute of Neurological Disorders and Stroke and others; MGTX...
Myasthenia gravis: past, present, and future
Bianca M. Conti‐Fine, Monica Milani, Henry J. Kaminski · 2006 · Journal of Clinical Investigation · 673 citations
Myasthenia gravis (MG) is an autoimmune syndrome caused by the failure of neuromuscular transmission, which results from the binding of autoantibodies to proteins involved in signaling at the neuro...
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis
Amelia Evoli · 2003 · Brain · 606 citations
The term seronegative myasthenia gravis (SNMG) refers to the generalized disease without detectable anti-acetylcholine receptor (anti-AChR) antibodies. In these patients, IgG antibodies against the...
IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†
Maria Isabel Leite, Saiju Jacob, Stuart Viegas et al. · 2008 · Brain · 505 citations
Only around 80% of patients with generalized myasthenia gravis (MG) have serum antibodies to acetylcholine receptor [AChR; acetylcholine receptor antibody positive myasthenia gravis (AChR-MG)] by t...
Guidelines for treatment of autoimmune neuromuscular transmission disorders
Geir Skeie, Slobodan Apostolski, Amelia Evoli et al. · 2010 · European Journal of Neurology · 498 citations
Background: Important progress has been made in our understanding of the autoimmune neuromuscular transmission (NMT) disorders; myasthenia gravis (MG), Lambert–Eaton myasthenic syndrome (LEMS) and ...
Reading Guide
Foundational Papers
Start with Hoch et al. (2001) for MuSK discovery (1172 citations); Evoli (2003) for clinical correlates (606 citations); Conti-Fine et al. (2006) for NMJ pathophysiology (673 citations).
Recent Advances
Sanders et al. (2016) consensus guidelines (1068 citations); Guptill et al. (2011) treatment cohorts (374 citations); Dresser et al. (2021) epidemiology update (401 citations).
Core Methods
125I-immunoprecipitation (McConville 2004); cell-based assays (Leite 2008); clinical scoring via QMG scales (Sanders 2016); rituximab B-cell depletion monitoring.
How PapersFlow Helps You Research MuSK Antibodies in Seronegative Myasthenia Gravis
Discover & Search
Research Agent uses citationGraph on Hoch et al. (2001) to map 1172-citing papers, revealing Evoli (2003) phenotype clusters; exaSearch queries 'MuSK MG bulbar rituximab response' surfaces Guptill et al. (2011) cohorts; findSimilarPapers expands from McConville (2004) detection methods.
Analyze & Verify
Analysis Agent runs readPaperContent on Sanders (2016) guidelines, verifying rituximab superiority via GRADE scoring (high evidence); runPythonAnalysis extracts titer-response correlations from Evoli (2003) datasets using pandas; verifyResponse/CoVe cross-checks claims against 10 MuSK papers reducing hallucination by 85%.
Synthesize & Write
Synthesis Agent detects gaps in thymectomy efficacy for MuSK-MG versus AChR-MG (Wolfe 2016), flags contradictions in inhibitor response; Writing Agent applies latexSyncCitations to draft review with 20 refs, latexCompile generates PDF, exportMermaid diagrams MuSK signaling disruption.
Use Cases
"Extract MuSK titer data from seronegative MG cohorts for statistical analysis"
Research Agent → searchPapers 'MuSK antibodies seronegative' → Analysis Agent → readPaperContent (Evoli 2003, Guptill 2011) → runPythonAnalysis (pandas correlation titer vs. bulbar score) → matplotlib remission plot.
"Write LaTeX review on MuSK-MG treatment guidelines"
Synthesis Agent → gap detection (Sanders 2016 vs. Skeie 2010) → Writing Agent → latexEditText (add bulbar section) → latexSyncCitations (15 papers) → latexCompile → downloadable review PDF.
"Find code for MuSK antibody ELISA simulation"
Research Agent → searchPapers 'MuSK antibody assay code' → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis (reproduce detection sensitivity from McConville 2004).
Automated Workflows
Deep Research workflow scans 50+ MuSK papers via citationGraph from Hoch (2001), outputs structured report with GRADE tables on rituximab (Sanders 2016). DeepScan's 7-step chain verifies bulbar phenotype claims across Evoli (2003)/Guptill (2011) with CoVe checkpoints. Theorizer generates hypotheses on MuSK IgG4 fragmentation from Conti-Fine (2006) signaling data.
Frequently Asked Questions
What defines MuSK-positive seronegative MG?
MuSK antibodies target muscle-specific kinase in AChR-seronegative generalized MG patients, detected via immunoprecipitation or cell-based assays (Hoch et al., 2001; McConville et al., 2004).
What are main detection methods?
125I-MuSK immunoprecipitation identifies 70% cases; cell-based assays detect low-affinity IgG4 (Leite et al., 2008; McConville et al., 2004).
What are key papers?
Hoch et al. (2001, 1172 citations) discovered MuSK antibodies; Evoli (2003, 606 citations) defined bulbar phenotype; Sanders et al. (2016, 1068 citations) guide rituximab use.
What open problems exist?
Standardized assays for low-titer detection; predictors of rituximab remission; mechanistic links between MuSK disruption and bulbar predominance (Guptill et al., 2011; Skeie et al., 2010).
Research Myasthenia Gravis and Thymoma with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching MuSK Antibodies in Seronegative Myasthenia Gravis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Myasthenia Gravis and Thymoma Research Guide